A Limited, First-in-Man, Phase IB Evaluation of BMTP-11 in Patients With Castrate-Resistant Prostate Cancer With High-Volume Osseous Metastases and no Standard Treatment Options.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 13 Jan 2014
At a glance
- Drugs BMTP 11 (Primary)
- Indications Cancer metastases; Prostate cancer
- Focus Adverse reactions
- 13 Jan 2014 Planned End Date changed from 1 Mar 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
- 19 Sep 2012 Planned end date changed from 1 Mar 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
- 17 Sep 2011 Status changed from recruiting to active, no longer recruiting reported by ClinicalTrials.gov..